Zobrazeno 1 - 10
of 12 207
pro vyhledávání: '"GlaxoSmithKline"'
Autor:
Academic Partners, Bonten, Marc, Davies, Kerrie A., Wilcox, Mark H., Kuijper, Ed, Rupnik, Maja, Wingen-Heimann, Sebastian, Tacconelli, Evelina, Vilken, Tuba, Petrosillo, Nicola, EFPIA Partners, Pfizer Ltd, GlaxoSmithKline, bioMérieux, Pasteur, Sanofi, Da Volterra, The Management Board of COMBACTE-CDI, Cleuziat, Philippe, Webber, Chris, Wingen-Heimann, Sebastian M., Davies, Kerrie, Viprey, Virginie F., Davis, Georgina, Vehreschild, Maria J.G.T., Lurienne, Lise, Bandinelli, Pierre-Alain, Cornely, Oliver A., Hopff, Sina M., Vehreschild, Jörg Janne
Publikováno v:
In Clinical Microbiology and Infection May 2023 29(5):651-651
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sebastian M. Wingen-Heimann, Kerrie Davies, Virginie F. Viprey, Georgina Davis, Mark H. Wilcox, Maria J.G.T. Vehreschild, Lise Lurienne, Pierre-Alain Bandinelli, Oliver A. Cornely, Tuba Vilken, Sina M. Hopff, Jörg Janne Vehreschild, null Academic Partners, Marc Bonten, Kerrie A. Davies, Ed Kuijper, Maja Rupnik, Sebastian Wingen-Heimann, Evelina Tacconelli, Nicola Petrosillo, null EFPIA Partners, null Pfizer Ltd, null GlaxoSmithKline, null bioMérieux, Sanofi Pasteur, null Da Volterra, null The Management Board of COMBACTE-CDI, Philippe Cleuziat, Chris Webber
Publikováno v:
Clinical microbiology and infection
Objectives: Clostridioides difficile infection (CDI) is one of the leading nosocomial infections worldwide, resulting in a significantly increasing burden on the healthcare systems. However, Pan-European data about cost and resource utilization of CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1859db01513111432eb169cbb121eae
https://hdl.handle.net/10067/1974680151162165141
https://hdl.handle.net/10067/1974680151162165141
Autor:
Kyle G. Mitchell, Edwin R. Parra, Jiexin Zhang, David B. Nelson, Erin M. Corsini, Pamela Villalobos, Cesar A. Moran, Ferdinandos Skoulidis, Ignacio I. Wistuba, Junya Fujimoto, Jack A. Roth, Mara B. Antonoff, J. Jack Lee, Ara A. Vaporciyan, Wayne L. Hofstetter, Reza J. Mehran, Stephen G. Swisher, David C. Rice, Boris Sepesi, Garrett L. Walsh, Carmen Behrens, Neda Kalhor, Annikka Weissferdt, John V. Heymach, null AstraZeneca, null Bayer, null GlaxoSmithKline
Publikováno v:
Ann Thorac Surg
BACKGROUND: Mutations in the serine-threonine kinase LKB1/STK11 have been implicated in mediating resistance to checkpoint blockade among patients with advanced lung adenocarcinoma. We sought to examine the associations between clinicopathologic char
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a544366045570a96adb06eb26cac2cdb
https://doi.org/10.1016/j.athoracsur.2020.03.114
https://doi.org/10.1016/j.athoracsur.2020.03.114
Autor:
N.M. Nenasheva Nenasheva, GlaxoSmithKline Trading Jsc, Moscow, Russia, S.V. Fedosenko Fedosenko, Immunology, Moscow, Russia, E.N. Barabanova Barabanova
Publikováno v:
Pharmateca. :125-132
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2257b7f2263e0fc2433ce2c50a52daf
https://doi.org/10.18565/pharmateca.2020.10.125-132
https://doi.org/10.18565/pharmateca.2020.10.125-132
Autor:
Malyavin A.G. Malyavin, Moscow GlaxoSmithKline Trading Jsc, Sharapova Yu.A. Sharapova, Kozulina I.E. Kozulina
Publikováno v:
Therapy. :195-205
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::720b9d92ceec98835503c0142b52aff6
https://doi.org/10.18565/therapy.2020.5.195-205
https://doi.org/10.18565/therapy.2020.5.195-205
Publikováno v:
Bulletin des Médecins Suisses.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a59d899d99f5b66ebbb72a53dfe921b3
https://doi.org/10.4414/bms.2019.18287
https://doi.org/10.4414/bms.2019.18287
Publikováno v:
Schweizerische Ärztezeitung.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b1a0328a2f631a93a843cb1882d5598
https://doi.org/10.4414/saez.2019.18287
https://doi.org/10.4414/saez.2019.18287
Autor:
Charles K. Fisher, Aaron M. Smith, Jonathan R. Walsh, Coalition Against Major Diseases, Abbott, Alliance for Aging Research, Alzheimer’s Association, Alzheimer’s Foundation of America, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Critical Path Institute, CHDI Foundation, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Forest Research Institute, Genentech, Inc., GlaxoSmithKline, Johnson & Johnson, National Health Council, Novartis Pharmaceuticals Corporation, Parkinson’s Action Network, Parkinson’s Disease Foundation, Pfizer, Inc., sanofi-aventis. Collaborating Organizations: Clinical Data Interchange Standards Consortium (CDISC), Ephibian, Metrum Institute.
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-14 (2019)
Scientific Reports
Scientific Reports
Most approaches to machine learning from electronic health data can only predict a single endpoint. The ability to simultaneously simulate dozens of patient characteristics is a crucial step towards personalized medicine for Alzheimer’s Disease. He
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c101fc21a20ed8ce94b12dcb5a5ec42a
https://doi.org/10.1038/s41598-019-49656-2
https://doi.org/10.1038/s41598-019-49656-2
Autor:
Fisher, Charles K, Smith, Aaron M, Walsh, Jonathan R, Coalition Against Major Diseases, Abbott, Alliance for Aging Research, Alzheimer’s Association, Alzheimer’s Foundation of America, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Critical Path Institute, CHDI Foundation, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Forest Research Institute, Genentech, Inc., GlaxoSmithKline, Johnson & Johnson, National Health Council, Novartis Pharmaceuticals Corporation, Parkinson’s Action Network, Parkinson’s Disease Foundation, Pfizer, Inc., sanofi-aventis. Collaborating Organizations: Clinical Data Interchange Standards Consortium (CDISC), Ephibian, Metrum Institute.
Publikováno v:
Scientific reports, vol 9, iss 1
Most approaches to machine learning from electronic health data can only predict a single endpoint. The ability to simultaneously simulate dozens of patient characteristics is a crucial step towards personalized medicine for Alzheimer's Disease. Here
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::b741e1b4d91874089ef97d675f158f16
https://escholarship.org/uc/item/9gr9344s
https://escholarship.org/uc/item/9gr9344s
